Patent · US Active

Sulfonamide analogues of galiellalactone

US10781197B2 · kind B2 · utility

0Cited by

1References

19Claims

0Family size

Assignee

GLACTONE PHARMA DEVELOPMENT AB · SE

Inventors

Martin Johansson · Helsingborg, SE
Olov Sterner · Eidsvold, AU

Key dates

Filing date	Dec 5, 2017
Grant date	Sep 22, 2020
Priority date	—
Expiry date	Dec 5, 2037

Classification

Technology area (CPC C)Chemistry; Metallurgy
CPC primaryC07D413/12
WIPO fieldPharmaceuticals
WIPO sectorChemistry

Abstract

Disclosed are sulfonamide analogues of galiellactone of formula (I) as STAT3-inhibitors for use in the treatment of a STAT3 signaling related disorder, e.g. solid cancers, hematological cancers, benign tumors, hyperproliferative diseases, inflammations, autoimmune diseases, graft or transplant rejections, delayed physiological function of grafts or transplants, neurodegenerative diseases and viral infections. The sulfonamide comprises a cyclic substituent.

Source: USPTO / EPO open patent data. Objective bibliographic and citation counts.